Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.4.0.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
REVENUES        
Neurometric Services $ 20,700 $ 20,900 $ 45,400 $ 43,700
OPERATING EXPENSES        
Cost of neurometric services revenue 1,400 1,800 2,700 2,900
Research 22,700 22,900 45,300 46,700
Product development 183,000 191,900 306,400 437,500
Sales and marketing 133,000 175,200 256,100 264,900
General and administrative 370,600 409,200 749,600 851,900
Total operating expenses 710,700 801,000 1,360,100 1,603,900
OPERATING LOSS (690,000) (780,100) (1,314,700) (1,560,200)
OTHER INCOME (EXPENSE):        
Interest expense, net $ (239,600) $ (54,600) (739,800) $ (106,000)
Loss on extinguishment of debt (2,337,400)
Gain on derivative liabilities $ 786,900 $ 139,200 798,200 $ 99,300
Total other income (expense) 547,300 84,600 (2,279,000) (6,700)
LOSS BEFORE PROVISION FOR INCOME TAXES $ (142,700) (695,500) (3,593,700) (1,566,900)
Provision for income taxes 800 300 4,000
NET LOSS $ (142,700) $ (696,300) $ (3,594,000) $ (1,570,900)
BASIC AND DILUTED LOSS PER SHARE:        
From continuing operations (in dollars per share) $ 0.00 $ (0.01) $ (0.04) $ (0.02)
WEIGHTED AVERAGE SHARES OUTSTANDING:        
Basic and Diluted (in shares) 102,669,022 101,667,409 102,543,215 101,667,409